Shares of Divi’s Laboratories are in focus after an update in the legal proceedings surrounding Novartis’ heart failure drug Entresto. Novartis and MSN Laboratories have reached a settlement on the ‘659 patent, which was one of the key patents protecting Entresto.
With this settlement, attention now shifts to the next patent in the litigation timeline. The subsequent patent is set to expire in November 2026, with associated regulatory exclusivity extending until May 2027.
According to analysts, this development could lead to potential upward revisions in Divi’s financial estimates for FY26 and FY27, depending on how the litigation progresses and market dynamics evolve in the coming quarters.
Divi’s Laboratories shares traded in a narrow range today, opening at ₹6,548 and, at the time of writing, reached an intraday high of ₹6,640.50. The stock touched a low of ₹6,513 during the session. It remains close to its 52-week high of ₹6,862.50, while the 52-week low stands at ₹4,395.30.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
